Brain scan monitoring for HER2-positive breast cancer
Part of Cancer clinical trials.
This study is testing regular MRI brain scans to find any brain metastases early in people with HER2-positive breast cancer that has spread. It aims to see if early detection can help guide treatment and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years of age or older.
- You have HER2-positive breast cancer that has spread to other parts of the body (metastatic).
- You are currently receiving HER2-targeted therapy.
- You have not had brain metastases or symptoms suggesting brain involvement.
- You are able to undergo MRI scans and have an ECOG performance status of 0-2.
- Your doctor expects you to live more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether regular brain scans (surveillance) help spot brain metastases early in people with HER2-positive breast cancer that has spread to other parts of the body. Participation involves being randomly assigned to either routine brain scans or no extra scans to see which approach is better.
This trial tests whether regular brain MRI scans can help detect brain metastases early in patients with stage IV breast cancer who do not yet have any known brain metastases. The goal is to see if early detection improves outcomes.
This study is looking at whether routine brain scans (MRI) at the time of diagnosis of metastatic breast cancer can help detect brain metastases early, even before they cause symptoms. It aims to understand how common brain metastases are in high-risk breast cancer and whether early detection can help guide treatment decisions. This may be relevant for people with certain types of breast cancer that have spread to other organs.
This trial checks whether taking screening brain MRI scans in people with stage IV breast cancer helps find brain involvement earlier. It may help guide treatment decisions for those who would otherwise only get brain imaging after symptoms start.
This trial uses an MRI scan to look for early signs of breast cancer spreading to the brain in people with certain aggressive breast cancer types (triple-negative or HER2-positive) that are stage IIb or III. The goal is to find and treat brain metastases earlier, before they cause symptoms.
This trial tests a special PET/MRI imaging scan using a labeled drug to help doctors evaluate HER2+ breast cancer that has spread to the brain. It focuses on patients who plan to receive fam-trastuzumab deruxtecan, a targeted cancer medicine, and aims to see how well the scan can support treatment decisions.
Hear when a new HER-2 Positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.